Loading clinical trials...
Loading clinical trials...
A Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 6727 Administered Intravenously in Asian Patients With Various Solid Cancers With Repeated Administration in Patients With Clinical Benefit
Conditions
Interventions
BI 6727
Locations
2
Taiwan
1230.16.886002 Boehringer Ingelheim Investigational Site
Tainan, Taiwan
1230.16.886001 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
Start Date
August 1, 2009
Primary Completion Date
September 1, 2011
Completion Date
September 1, 2011
Last Updated
July 26, 2019
NCT00026884
NCT07213804
NCT07169851
NCT07159659
NCT07191730
NCT06662786
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions